Hidehito HORINOUCHI
@HHorinouchi
Followers
3K
Following
10K
Media
1K
Statuses
3K
Medical Oncologist, @NCCJ_official, @JCOG_official, Education committee @JSMO_official @JLCS_OFFICIAL @IASLC @ASCO FCOI https://t.co/c9VKywUIsh
Tsukiji, Tokyo, Japan
Joined May 2010
The IASLC Hot Topic Meeting in #Tokyo is almost here! Join leading experts to explore early #lungcancer #research, from molecular mechanisms to new therapeutic strategies. Register now ➡️ https://t.co/ej5hvHJxYu
#IASLC #Oncology
0
2
6
🔥🚨#November is 🫁 #LungCancerAwareness Month. Lung Cancer Awareness #SavesLives. Together, WITH #Patients, we keep the #Fight against #LungCancer. We have made a great #Progress but still have a long way to go. #LCAM25 👇🏼Sharing, like every year, my #AWARENESS #Mnemonic
3
37
61
It’s Lung Cancer Awareness Month! 🤍 Lung cancer remains the #1 cancer killer worldwide, but millions of patients, clinicians, and researchers are fighting back every day. Join them. Support the IASLC Foundation. Donate now: https://t.co/BcrFYsuhRJ
0
21
41
Fantastic energy this week presenting preliminary findings from our SOLARA trial of BH-30643 in Boston. Please check out the poster which is now on the BHT pipeline website! Study enrolling full steam ahead with a focus on on-target resistance and TKI-naive #EGFR-mutant NSCLC.
2
3
32
Fond memories of #ACLC25 in Vietnam thanks to @FengMingKong, @t_mitsudomi, @HHorinouchi and entire @IASLC team. Special thanks to my partners @LiisaBergmann, @chulkimMD & @maraantonoff for pulling off spectacular multiD thymic malignancy workshop.
2
2
17
Thank you @JAMA_current for highlighting the issue of lung cancer in people who have never smoked. Podcast with JAMA deputy editor Dr Kristin Walter discussing the article available online.
Lung cancer among nonsmoking individuals accounts for 15% to 20% of all lung cancer cases. Benjamin Solomon, PhD, of @PeterMacCC, discusses this and more with JAMA Deputy Editor Kristin Walter, MD, MS. 🎧 Listen now: https://t.co/OIM2NPdOG0
1
10
35
Your IASLC community is waiting. 🌎 Join Thoracic Circle and connect, collaborate, and grow with members from 100+ countries. Start connecting today 👉 https://t.co/Z5HsEwHL5Y
#IASLC #ThoracicCircle #LungCancer
0
2
11
📣 All #ESMO25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO Watch on demand and stay at the forefront of oncology. 🔗 https://t.co/Xb4tjHltTC
2
23
70
In this episode of #LungCancerConsidered, @MNagasaka speaks with @HHorinouchi in Japanese about key findings and clinical insights presented at #WCLC25. 🎧 https://t.co/HFXUFb2Avk
0
6
20
Reactions on top trials during @myESMO 2025, curated by @Larvol CLIN. Explore more insights and OncoBuzz trends from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology | @SuyogCancer| @ArmandOrlandi
0
14
27
Top Women Oncologists based on the most 𝕏 viewed posts during @myESMO 2025 Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 | @nataliagandur |
1
5
15
Top Cancer Institutes on 𝕏 during @myESMO 2025, based on oncologists' posts and views. Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 | @DanaFarber
0
19
57
Top Lung Cancer Oncologists from @myESMO 2025 Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #LungCancer | @StephenVLiu | @HHorinouchi | @Tony_Calles
0
14
27
@myESMO 2025 Recap: Top ADC Trials and Key Results Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #ADCs | @StephenVLiu | @ErikaHamilton9 | @DrSGraff
0
8
18
🚀 EGFR-mutant lung cancer: the landscape is being rewritten. #ESMO25 Read the full post here ⤵️
linkedin.com
🚀 EGFR-mutant lung cancer: the landscape is being rewritten. During #ESMO25, in front of more than 9,000 colleagues attending the Presidential Session II, I had the honor to serve as discussant for...
1
8
38
#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting. #ESMODailyReporter ➡️ https://t.co/QV4mEcq3CY
0
2
5
The #OncoAlertTopTweet 🚨 Day FOUR #ESMO25 Post from OncoAlert Faculty @HHorinouchi 🇯🇵 ALINA: Updated from phase III adjuvant alectinib vs chemotherapy in pts with early-stage ALK+ #NSCLC #LungCancer
@nataliagandur @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth
🆙 #ESMO25 🇩🇪 🔥#LCSM Mini Oral, non mets ☑️ALINA: Updated from phase III adjuvant alectinib vs chemotherapy in pts with early-stage ALK+ NSCLC 🎯DFS IB-IIIA HR 0.35 (95%CI 0.23–0.54), OS HR 0.40 (95%CI 0.12–1.32) 🎙️ Dr. Rafal Dziadziuszko @OncoAlert @myESMO @Larvol
0
7
11
The #OncoAlertTopTweet 🚨 Day FOUR #ESMO25 Post from @graokane 🇮🇪🇨🇦 ABBV-400;Temab-A;c-MET targeting ADC (TOPO1i payload) #PDAC
@nataliagandur @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas
ABBV-400;Temab-A;c-MET targeting ADC (TOPO1i payload) #PDAC ➡️all pretreated pts ➡️ORR 24% ; ⬆️post GnP v mFFX🤔40% v15% Small no. Or real? ➡️tissue mod/high exp c-met ➡️more efficacy data to come ➡️AEs manageable, nausea + haem ⭐️Exciting potential new tx #ESMO25 @OncoAlert
0
7
13
On behalf of the Network, We would like to thank OUR #OncoAlertAF 🚨 for their amazing coverage of #ESMO25 🇩🇪 WE ARE #OncoAlertAF ‼️ 🇺🇸 @WeOncologists 🇧🇪 @ElisaAgostinett 🇦🇷 @nataliagandur 🇮🇹 @to_be_elizabeth 🇯🇵 @HHorinouchi 🇪🇸 @MarioBalsaMD 🇪🇸 @DrMirallas 🇺🇸
We are in Berlin for #ESMO25 The OncoAlert AF 🚨is proud to bring you all the great science coming out of Germany🇩🇪 and thanks you for your Support! We encourage you to follow these outstanding colleagues, and—as always—OncoAlert is on the ground reporting in real time on all
0
12
28
The #OncoAlertTopTweet 🚨 Day FOUR #ESMO25 Post from OncoAlert Faculty @HHorinouchi 🇯🇵 DS-3939: Tumor-associated mucin 1 (TA-MUC1)–directed ADC. Initial results from a first-in-human study @nataliagandur @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus
🆙 #ESMO25 🇩🇪 🔥#LCSM Proffered paper: Develop Tx ☑️DS-3939: Tumor-associated mucin 1 (TA-MUC1)–directed ADC. Initial results from a first-in-human study 🎙️ Dr. Manish R. Patel @OncoAlert @myESMO @Larvol
0
6
15